Skip to main content

Analyst Begins Covering Fisher, Says Record of Growth Warrants Outperform Rating

NEW YORK, June 3 (GenomeWeb Daily News) - An analyst for Leerink Swann  initiated coverage of Fisher Scientific, and has given the company an 'Outperform' rating, the investment bank said today.


John Sullivan, senior biotechnology and life sciences analyst for Leerink Swann said Fisher's "record of internal and acquired growth, the expansion of its strong franchise in life science consumables, and its strategy of adding higher margin products to its mix" fueled his decision.


Fisher acquired  proteomics shop Perbio in 2003 and  RNAi tools provider Dharmacon one year later. As GenomeWeb News reported last week, the company said it is eyeing potential acquisitions as it continues to look for ways to grow its footprint in the life-sciences market.


Fisher said it is focusing on higher-growth consumables plays in the molecular biology tools field, Vice Chair Paul Meister said during a recent investor conference.


He said Fisher expects $400 million in cash flow this year, which would ensure the company is flexible for any potential acquisition targets that come its way.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.